Key Observations from Phase 2 Data Dose escalation reduced adverse events: Groups that used gradual dose titration reported fewer GI events than those starting at the target dose directly No deaths were attributed to the study drug Serious adverse events were reported at low rates across all groups, with no clear dose-dependent pattern for serious events The placebo group also reported substantial adverse events (72.1%), which is typical for trials of this size and duration TRIUMPH Phase 3 Adverse Event Profiles The TRIUMPH program consists of eight Phase 3 trials evaluating retatrutide across multiple indications including obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD)
Are there supplements or foods I should avoid, or be taking, due to this drug
The following peptides are promising for combination with Semaglutide: Insulin-sensitizing peptides (e.g., analogs of GLP-1, GIP, or related peptides) may complement semaglutides glucose-lowering effects
The combination works because both pathways converge on the same somatotroph cells at the same moment
Prepare for your appointment by documenting your current symptoms, particularly those related to weight management, energy levels, and metabolic health